Modality
ADC
MOA
TROP-2 ADC
Target
DLL3
Pathway
Complement
Migraine
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
~Mar 2021
→ ~Jun 2022
Phase 2
~Sep 2022
→ ~Dec 2023
Phase 3
~Mar 2024
→ ~Jun 2025
NDA/BLA
Sep 2025
→ May 2026
NDA/BLACurrent
NCT05209949
593 pts·Migraine
2025-09→2026-05·Terminated
593 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-05-071mo awayPh3 Readout· Migraine
Trial Timeline
Q42026Q2
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2026-05-07 · 1mo away
Migraine
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05209949 | NDA/BLA | Migraine | Terminated | 593 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 |